Shots:
Nuvectis has licensed exclusive ex-China rights to NXP100 (HSK39297; QD, PO), a Complement Factor B inhibitor, & NXP200 (HSK42360), a brain-penetrant paradox-breaker BRAF inhibitor from Haisco, transforming the company into a late-stage development player
As per the deal, Haisco will receive ~$40M in upfront & near-term payments, plus up to $1.421B in development,…
